<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hasanpourghadi M</submitter><funding>PPP grant</funding><pagination>e5577</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6147144</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6</volume><pubmed_abstract>Combination Index (CI) analysis suggested that MBIC and doxorubicin synergistically inhibited up to 97% of cell proliferation in ER&lt;sup>+&lt;/sup>/PR&lt;sup>+&lt;/sup>MCF-7 and triple negative MDA-MB-231 breast cancer cell lines. Moreover, treatment of the breast cancer cells with the combined drugs resulted in lower IC&lt;sub>50&lt;/sub> values in contrast to the individual drug treatment. Small noncoding microRNAs (miRNA) may function as non-mutational gene regulators at post-transcriptional level of protein synthesis. In the present study, the effect of the combined treatment of MBIC and doxorubicin on the expression level of several miRNAs including miR-34a, miR-146a, miR-320a and miR-542 were evaluated in MCF-7 and MDA-MB-231 breast cancer cell lines. These miRNAs have the potential to alter the pro</pubmed_abstract><journal>PeerJ</journal><pubmed_title>The role of miRNAs 34a, 146a, 320a and 542 in the synergistic anticancer effects of methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) with doxorubicin in breast cancer cells.</pubmed_title><pmcid>PMC6147144</pmcid><funding_grant_id>project number: PG048-2015A</funding_grant_id><pubmed_authors>Rais Mustafa M</pubmed_authors><pubmed_authors>Abdul Majid N</pubmed_authors><pubmed_authors>Hasanpourghadi M</pubmed_authors></additional><is_claimable>false</is_claimable><name>The role of miRNAs 34a, 146a, 320a and 542 in the synergistic anticancer effects of methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) with doxorubicin in breast cancer cells.</name><description>Combination Index (CI) analysis suggested that MBIC and doxorubicin synergistically inhibited up to 97% of cell proliferation in ER&lt;sup>+&lt;/sup>/PR&lt;sup>+&lt;/sup>MCF-7 and triple negative MDA-MB-231 breast cancer cell lines. Moreover, treatment of the breast cancer cells with the combined drugs resulted in lower IC&lt;sub>50&lt;/sub> values in contrast to the individual drug treatment. Small noncoding microRNAs (miRNA) may function as non-mutational gene regulators at post-transcriptional level of protein synthesis. In the present study, the effect of the combined treatment of MBIC and doxorubicin on the expression level of several miRNAs including miR-34a, miR-146a, miR-320a and miR-542 were evaluated in MCF-7 and MDA-MB-231 breast cancer cell lines. These miRNAs have the potential to alter the pro</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018</publication><modification>2026-06-13T05:46:42.404Z</modification><creation>2026-06-13T03:09:21.258Z</creation></dates><accession>S-EPMC6147144</accession><cross_references><pubmed>30245930</pubmed><doi>10.7717/peerj.5577</doi></cross_references></HashMap>